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Figure 1: In vitro chondrogenesis of hMSCs. Results indicate a signiﬁcant
increase in GAG deposition and collagen type II expression with the
addition of TGFb3 HA microspheres. *p ¼ 0.05
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regulator in determining cell fate of human mesenchymal stem cells
(hMSCs), speciﬁcally down the chondrogenic lineage. Yet control of this
differentiation within a complex in vivo milieu remains a challenge. A
localized therapy such as an intra-articular injection of a system for
controlled release of TGF-b3 would represent a readily translatable
approach for in situ differentiation and remove the need for continuous
supplementation of growth factors. Hyaluronan (HA) is an essential
component of cartilage extracellular matrix (ECM) and serves as a
support for cell adhesion, spreading and subsequently, cell growth.
Thus, our aim was to fabricate chondromimetic HA microspheres and
test these as extracellular growth factor targeting depots for initiation of
in vitro and ex vivo chondrogenesis of hMSCs.
Methods:HAmicrospheres were fabricated using an electrostatic layer-
by-layer strategy and characterized by scanning electron microscopy.
hMSCs isolated from the iliac crest of healthy donors were obtained
with approval from the National University of Ireland Galway and
associated University College Hospital ethics committees and cultured
in a-MEM containing 10% FBS, 100U/ml penicillin and 100mg/ml
streptomycin. The effects of microspheres on cell number andmetabolic
activity were determined using the PicoGreen dsDNA and
alamarBlue assays. Confocal microscopy, ﬂow cytometry and trans-
mission electronmicroscopy were utilized to investigate co-localization
of HA microspheres with hMSCs to ensure they were not taken up by
cells. TGF-b3 was loaded onto HA microspheres via passive diffusion
(400ng/mg), incubated with hMSCs and cultured for 21 d in incomplete
chondrogenic medium (ICM) or complete chondrogenic medium (CCM)
(þ10ng/ml TGF-b3 every 2 d) to assess in vitro chondrogenesis. Gly-
cosaminoglycan (GAG) measurement (DMMB assay), chondrogenic
transcripts (qRT-PCR) and immunohistochemical staining (IHC) were
used to validate successful chondrogenesis. For ex vivo culture experi-
ments, fresh human articular cartilage samples were obtained under
institutionally approved protocols from Merlin Park Hospital, Galway
from donors who had undergone knee replacement surgery. Cartilage
explants were allowed to equilibrate at 37C for 48 h in Dulbecco’s
Modiﬁed Eagle’s Medium (DMEM) þ 10% fetal bovine serum and sub-
sequently equilibrated for 24 h in ICM in an agarose well prior to
switching to ICM or CCM media and treated with or without TGF-b3
loaded microspheres for 21 d culture. Experiments were performed for
3 donors with each experiment containing a minimum of three bio-
logical replicates. Statistical signiﬁcance was assessed using one-way orFigure 2: Ex-vivo culture of human articular cartilage explants for 21 d in
ICM with human mesenchymal stems with or without TGFb3 loaded HA
microspheres.two-way ANOVA followed by Tukey or Bonferroni post hoc analysis and
denoted signiﬁcant for p ¼ 0.05.
Results: HA microspheres retained their spherical morphology with
uniform size distribution. Cellular compatibility studies indicated no
adverse effects of 10mm HA microspheres. Following TGF-b3 loading of
microspheres, incubation with hMSCs for 21 d in vitro pellet culture
revealed enhanced accumulation of GAGs (Fig. 1A) and positive IHC of
collagen type II in hMSCs incubated with growth factor loaded HA
microspheres when compared to control cells. Additionally, qRT-PCR
analysis from 14 d pellets revealed enhanced expression of aggrecan
and collagen type II (Fig. 1B). 21 d explant culture indicated localization
of TGF-b3 HA microspheres within ﬁbrillations of osteoarthritic carti-
lage with implanted hMSCs and local chondrocytes showing increased
GAG deposition compared to hMSCs alone (Fig. 2, arrow indicative of
increased GAG staining in surrounding cells).
Conclusion: Injectable biomaterials hold great promise for orthopaedic
applications, in particular for repair of articular cartilage. Preliminary in
vitro/ex-vivo evidence presented here supports the use of TGF-b3-
loaded HA microspheres for in situ differentiation of hMSCs.
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PRODUCING ARTIFICIAL CHONDRONS FOR IMPROVED CARTILAGE
REPAIR
T. Kamperman, J.C. Leijten, S.J. Henke, M. Karperien. Univ. of Twente,
Enschede, Netherlands
Purpose: Articular cartilage has a limited capacity for self-repair and
untreated damage often leads to the development of osteoarthritis and
eventually joint failure. Currently, autologous chondrocyte implanta-
tion is the most successful method for repairing focal cartilage defects.
This therapy involves the isolation of chondrocytes from articular car-
tilage by enzymatic degradation. This not only strips the cells from their
extra cellular matrix, but also from their highly specialized micro-
environments, called chondrons. This initiates dedifferentiation, i.e. the
isolated chondrocytes progressively lose their chondrogenic phenotype,
and thus reduces the clinical success of the therapy. We aim to develop
a strategy to encapsulate expanded single chondrocytes in artiﬁcial
chondrons. When successful, this approach represents a cost-effective
method to prevent further dedifferentiation, while simultaneously
allows for optimal stimulation of the encapsulated chondrocytes. Here,
we present a microﬂuidic device able to encapsulate single chon-
drocytes in chondron-sized (<50 mm) microgels in a custom designable
artiﬁcial matrix using an efﬁcient and cell-friendly manner.
Methods: The master mould for the optimized microﬂuidic droplet
generator was made by micropatterning w25 mm thick SU8-50
(MicroChem) on a silicon wafer using standard photolithography
techniques. PDMS (Sylgard 184, Dow Corning) was thermally cured on
the master and bonded to glass after plasma treatment. Aquapel (Vul-
cavite) was introduced in the chip before usage to ensure hydrophobic
channels walls. We compared various combinations of oils, surfactants,
photoinitiators and UV dosages, as these are of paramount importance
to obtain chondron-sized microgels. Chondron-sized droplets were
produced by emulsifying a chondrocyte-laden hydrogel precursor sol-
ution of 10% (w/v) polyethylene glycol diacrylate (PEGDA, Laysan Bio,
Inc.) and 0.1% (w/v) photoinitiator (Irgacure 2959, Ciba Specialty
Chemicals) in hexadecane (Sigma) with 1% Span80 (Sigma). Sub-
sequently, the microgels were formed in an on-chip delay channel by
curing the emulsion with 365nm UV-light (Hamamatsu LC8).
Results: Chondrocytes were encapsulated in PEGDA microgels using
droplet microﬂuidics at a rate of typically 20,000 cells per minute. The
number of encapsulated cells followed a Poisson-distribution that was
dependent on the cell concentration. We aimed to minimize the
microgels’ dimensions by comparing different combinations of oils,
surfactants and UV dosages. Fluorinated oils in combination with
PEGylated ﬂuorosurfactants resulted in the most stable emulsions and
thus allowed for the lowest photoinitiator concentration and UV dose
for cell-laden microgel production. However, the use of ﬂuorinated oils
resulted in relatively large gels, which is a consequence of their low
viscosity compared to the hydrogel precursor solution. In contrast, the
use of a more viscous hydrocarbon oil with Span80 surfactant resulted
in smaller, chondron-sized microgels. However, emulsions with this oil/
surfactant combination were less stable off-chip. Solid on-chip cross-
linking was accomplished by using an extended delay channel which
enabled prolonged UV radiation without compromising the production
rate. Finally, by varying the ﬂow rates of the continuous and dispersed
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monodisperse PEGDAmicrogels with a controlled diameter between 30
and 50 mm in a cell-friendly manner.
Conclusions: We have developed a microﬂuidic platform and opti-
mized the production process for the encapsulation of single chon-
drocytes in chondron-sized microgels at a typical rate of 20,000 cells
per minute. Future work will focus on the functionalization of the
microenvironment within the biomaterial by means of incorporation of
growth factors and extracellular matrix molecules to create biomimetic
and chondrogenic artiﬁcial chondrons.
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OXYGEN IS A CRITICAL PARAMETER FOR CHONDROGENIC
DIFFERENTIATION OF HUMAN UMBILICAL CORD BLOOD
MESENCHYMAL STEM CELL IN 3D-CULTURES
T. Gomez-Leduc y, M. Hervieu y, M. Desance y, C. Drougard y,
D. Ollitrault y, L. Poulain z, F. Legendre y, P. Galera y, M. Demoor y. y Lab. of
Cellular Microenvironnement and Pathologies (MILPAT), Caen, France;
zBIOTICLA-UCBN, Caen, France
Purpose: The autologous chondrocyte implantation technique presents
many limitations for cartilage disease treatment. The surgical process is
traumatic and few chondrocytes are harvested. Mesenchymal stem cells
(MSCs) represent a promising clinical tool for cartilage regeneration and
osteoarthritis (OA) therapy. Although adult bonemarrow has been up to
now the main source of MSCs, their harvest is also a highly invasive
procedure and their number, differentiation potential, and maximal life
span decline with increasing age. The umbilical cord blood mesen-
chymal stem cells (UCB-MSCs) are a promising alternative source, due
to abundant resources, painless and non-invasive collection process and
are rapidly expandable in in vitro cultures. The aim of our study was to
determine the chondrogenic differentiation potential of human UCB-
MSCs for cartilage tissue engineering.
Methods: The UCB were collected after full term and normal delivery
pregnancy. Cell ampliﬁcation, karyotype, osteoblasts and adipocytes
differentiation of UCB-MSCs were realized in normoxia. XTT cell assay
was performed after 7 days under normoxic (21% O2) or hypoxic (< 5%
O2) culture conditions. Cumulative population doublings and several
surface markers of MSCs were analyzed up to the seventh passage. The
chondrogenic differentiationwas induced using an innovative approach
combining 3D-culture in type I collagen sponges and chondrogenic
factors (BMP-2  TGF-ß1) in normoxia or in hypoxia. Chondrogenic
differentiation was then evaluated by real-time RT-PCR, Western-blot-
ting and immunoﬂuorescence microscopy after 7, 14 and 21 days of cell
differentiation. The nature of the hyaline neo-tissue obtained after 14
days of in vitro differentiation was veriﬁed by subcutaneous implan-
tation in the nude mice. The neo-tissue was collected after 35 days and
histological examination was performed using hematoxylin-eosin-
safran and alizarin red, as well as type I- and II-collagen immunohis-
tochemistry analyses.
Results: 127 UCB samples were obtained with a mean volume of 41.15
 22.95 mL. Taking into account of only those with a minimal volume
of 55 mL, the success efﬁciency was enhanced from 30% to 57%. Flow
cytometry results showed that the isolated cells expressed CD29,
CD44, CD73, CD90, CD105, CD166 and did not express CD14, CD34,
CD45, CD64 and HLA-DR. There was no signiﬁcant variation of those
markers all along cell ampliﬁcation. Otherwise, CD146 expression was
shown to be donor- and passage-dependent. Interestingly, the growth
of hypoxic UCB-MSC in monolayers induced the formation of cell
spheres and a decrease in cell metabolism. Cells were shown to dif-
ferentiate mainly in osteoblasts but not in adipocytes. The addition of
BMP-2 and TGF-ß1 allowed to enhance chondrogenesis both in nor-
moxia and hypoxia. Surprisingly, differentiation occurred earlier and at
a higher level in normoxic compared to hypoxic conditions. These
observations were conﬁrmed by the analysis of 12 chondrogenic
related genes and type II collagen protein. An increase in expression of
speciﬁc cartilage markers (SOX9, COL2A1, COLIIB, ACAN et SNORC) and a
slight MMP13 expression were observed during the culture. Otherwise,
hypoxia presented beneﬁcial effects by decreasing type X collagen. All
the neo-tissue generated in vitro and injected in mice demonstrated
that cells treated with BMP-2 and TGF-ß1 in normoxia showed a better
phenotype maintenance with a more organized and abundant type II
collagen matrix. Alizarin red staining was negative for all the donors.
Conclusions:Our experiments demonstrated that UCB-MSCs could be a
reliable cell source for cartilage tissue engineering. In this sense, wesuggest that UBC-MSCs cultured in in vitro 3D-culture can begin
chondrogenesis in normoxic conditions to obtain a more efﬁcient
chondrogenic differentiation, before placing them in hypoxic conditions
to stabilize the phenotype before in vivo implantation.
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BLOCK OF ANGIOGENESIS ENHANCES IN VIVO CHONDROGENESIS OF
NASAL CHONDROCYTES-BASED CONSTRUCTS
C.M. Medeiros da Cunha y, V. Perugini z, P. Bernegger y, M. Centola y,
M. Santin z, A. Banﬁ y, I. Martin y, A. Marsano y. yUniv. Hosp. Basel, Basel,
Switzerland; zUniv. of Brighton, Brighton, United Kingdom
Background/Aim: Vascular Endothelial Growth Factor (VEGF) is
involved in regulating cartilage growth and endochondral ossiﬁcation
during growth plate development, but also in degenerative processes
e.g. in osteoarthritis or following mechanical overloading. On the other
hand, VEGF expression is suppressed during hyaline cartilage formation
and maintenance, and blocking of angiogenesis results in improved
cartilage repair inmurinemodels. We sought to investigatewhether the
sole blockade of the endogenous VEGF pathway could improve in vivo
chondrogenesis in engineered tissues based on nasal chondrocytes
(NC). Blockage of VEGF was achieved by transducing BMSC to express
soluble VEGF receptor-2 (sFlk-1).
Methods: Human NCs were retrovirus-transduced to overexpress the
soluble form of human VEGF receptor 2 (sFlk-1). Cell-based constructs
were generated with either sFlk-1-expressing or control cells loaded on
collagen-based scaffolds. To investigate their in vivo chondrogenenic
potential, the constructs were implanted in an ectopic mouse model.
Vessel formation, VEGF activity, cartilage biochemistry and histology
were performed to evaluate how the intrinsic chondrogenic capacity of
NCs could beneﬁt from blocking VEGF pathway.
Results: The released sFlk-1 blocked blood vessel ingrowth within the
implant. Blood vessel ingrowth was signiﬁcantly reduced in the engi-
neered tissues developed by sFlk-1-expressing cells compared to con-
trol cells. sFlk-1 did not appear to regulate the in vitro chondrogenic
differentiation of NCs. However, frank chondrogenesis in vivo could
only be observed in the constructs generated by NCs expressing sFlk-1.
Cartilaginous extracellular matrix was stable up to 8 weeks in vivo.
Conclusion: VEGF blockage was sufﬁcient to induce in vivo chondro-
genesis of NC in the absence of other exogenous morphogens. The long-
term stability of the generated cartilage requires further investigations.
The overexpression of sFlk-1 and the associated reduction in blood
vessel ingrowth has profound effects on in vivo chondrogenesis by NCs,
even in the absence of chondroinductive signals at the implant site. The
absence of such effect in the in vitro model suggests a predominant
paracrine mechanism, related to the control of angiogenesis by host
cells.
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ARE UMBILICAL CORD MESENCHYMAL STEM CELLS ADVANTAGEOUS
OVER BONE MARROW MESENCHYMAL STEM CELLS FOR CELL
THERAPY IN ORTHOPAEDICS?
C. Mennan y, S. Owen y, E. Mayrogonatou z, D. Kletsas z, R. Oldershaw x,
J. Richardson y, S. Roberts y. y ISTM & Keele Univ., Oswestry, United
Kingdom; zNatl. Ctr. for Scientiﬁc Res., Athens, Greece; xNewcastle Univ.,
Newcastle upon-tyne, United Kingdom
Purpose:Mesenchymal Stem cells (MSC) from umbilical cords (UC) are
of increasing interest for cell therapy in degenerative musculoskeletal
disorders as they present little ethical consideration and are reported to
contain immune privileged cells, which may be suitable for allogeneic
based therapies. The use of MSCs as allogeneic cells in vivo would only
be possible if they retained their immune privileged properties in an
inﬂammatory environment. We have previously shown that cells
obtained from UC are multipotent and have the recommended MSC cell
surface marker proﬁle according to the International Society for Cellular
Therapy. The focus of this study was to characterise the immune
properties of MSCs isolated from UC, particularly Wharton’s jelly (WJ)
and cells fromwhole cord (MC) as we have previously shown that cells
from these cord regions have the best multipotency. MC and WJ were
compared to Bone Marrow MSCs (BMSCs) in order to utilise the most
promising population of stem cells and to analyse the immune prop-
erties of these cells before and after stimulation with the pro-inﬂam-
matory cytokine, interferon-g (IFN-g).
